🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2-positive Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients NCT06722599n/a1 site📍 Beijing Shu Wang Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer NCT06123988NA3 sites📍 Phoenix📍 Miami📍 Boston University of Miami · Tests: Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease NCT07542496n/a2 sites📍 Algiers📍 Algiers Société Algérienne de Formation et Recherche en Oncologie Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer NCT07635342Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Pyrotinib Maleate, Trastuzumab (H, 8mg/kg, pegylated liposomal doxorubicin hydrochloride, Cyclophosphamide, Paclitaxel … DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients NCT06388122n/a1 site📍 Jacksonville Mayo Clinic · Tests: Biospecimen Collection Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer NCT07695259Phase 41 site📍 Hangzhou Wen-Ming Cao · Tests: olaparib combined with trastuzumab and pertuzumab I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites📍 Birmingham📍 Scottsdale📍 Tucson QuantumLeap Healthcare Collaborative · Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Tras… A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer NCT07455188n/a1 site📍 Zhejiang Zhejiang Cancer Hospital · Tests: Antitumor treatment plan Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer NCT06938724Phase 21 site📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Omission of local therapies SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases NCT04923542Phase 1, Phase 22 sites📍 Tampa📍 Columbus H. Lee Moffitt Cancer Center and Research Institute · Tests: Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites📍 La Jolla📍 Los Angeles📍 Port Saint Lucie Regor Pharmaceuticals Inc. · Tests: RGT-419B, RGT-419B in combination with hormonal therapy SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance NCT07503717NA1 site📍 Beaumont Royal College of Surgeons, Ireland · Tests: Brain Magnetic Resonance Imaging (MRI) with Contrast ARX788 in HER2-positive Metastatic Breast Cancer Patients NCT06663748Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: ARX788 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). NCT06217185Phase 41 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Pyrotinib, Trastuzumab, Taxanes, Capecitabine Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients NCT07233499Phase 21 site📍 Cairo Ain Shams University · Tests: Nebivolol 5 mg Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer NCT07214532NA49 sites📍 Phoenix📍 Scottsdale📍 Tucson Natera, Inc. · Tests: ctDNA-Guided Treatment Strategy Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites📍 Jonesboro📍 Little Rock📍 Duarte Celcuity Inc · Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Let… Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer NCT06837792Phase 21 site📍 Seoul Yonsei University · Tests: Experimental treatment arm, Control treatment arm A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer NCT07112053Phase 21 site📍 Seattle University of Washington · Tests: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4… TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer NCT07047365Phase 375 sites📍 Bengbu📍 Hefei📍 Hefei Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQB2930+ chemotherapy, Trastuzumab+ chemotherapy SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095Phase 21 site📍 Shanghai Fudan University · Tests: PIK3CA inhibitor, AKT inhibitor, Carrelizumab, Famitinib, Fluzoparib Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer NCT07276880Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer NCT05159193Phase 31 site📍 Guandong Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: pegylated liposomal doxorubicin (PLD), cyclophosphamide (C), trastuzumab (H), pertuzumab (P), docetaxel (T) Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer NCT05744687Phase 2, Phase 39 sites📍 Fuzhou📍 Guangzhou📍 Guiyang Shanghai Pharmaceuticals Holding Co., Ltd · Tests: SPH4336 Tablets 400mg, SPH4336 Tablets Placebo Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies NCT07211178n/a16 sites📍 Birmingham📍 Whittier📍 Weston Tempus AI · Tests: There are no interventions in this observational study. RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study NCT07030569n/a1 site📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Trastuzumab deruxtecan (DS-8201a) Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure NCT07708194Phase 1, Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: entinostat, Pyrotinib, endocrine therapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy